Loading clinical trials...
Loading clinical trials...
Phase Ib, Open-label Study of Add on Therapy With CK0804 in Participants With Myelofibrosis, With Suboptimal Response to Ruxolitinib
Conditions
Interventions
CK0804
Locations
4
United States
UC Davis Health
Sacramento, California, United States
Columbia University
New York, New York, United States
Montefiore Einstein Cancer Center
The Bronx, New York, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
December 27, 2022
Primary Completion Date
April 30, 2026
Completion Date
December 30, 2026
Last Updated
April 13, 2025
NCT06859424
NCT06343805
NCT05123365
NCT07104799
NCT05037760
NCT06164561
Lead Sponsor
Cellenkos, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions